Seraseq® Compromised FFPE Tumor DNA Reference Material

SeraCareSKU: SER-0710-1492

Price:
$1,480

Description

Comprehensive genomic profiling (CGP) is an important part of an integrated clinical management of cancer patients, where cancer patients harboring variants/biomarkers of clinical utility are determined by highly multiplexed targeted NGS assay testing. Precise analysis of these patient samples requires high quality sample-to-result assay workflow controls to guide and validate the accurate identification of these actionable variants.

LGC SeraCare has developed a highly multiplexed Compromised FFPE Tumor DNA reference material imbibing “patient-like” characteristics to support end-to-end NGS workflows performed by clinical labs in the analysis of cancer patient samples. This product consists of 17 genes and 34 variants, incorporating all variant types – SNVs, INDELs, CNVs, and SVs. These variants were precisely quantitated by digital PCR and targeted NGS against a single well-characterized genomic background (GM24385).

  • Highly multiplexed FFPE Tumor DNA reference material
  • Contains 34 variants in 17 genes
  • All variant types – SNVs (18), INDELs (10), CNVs (3) and SVs (3)
  • For use in sample-to-result NGS workflows to analyze for mutation-positive variants in patient samples
  • Manufactured in GMP-compliant ISO 13485 certified facility

 

Gene List
ATK1 EGFR MYC CD74-ROSI
ALK ERBB2 NRAS NCOA4-RET
BRAF KIT PIK3CA EML4-ALK
BRCA1 KRAS TP53
BRCA2 MET

 

Specifications:

Product Specifications - Compromised FFPE Tumor DNA RM
# of genes 17
Size 10 µm
Format FFPE
DNA Yield >100 ng*

*QIAamp FFPE Tissue DNA Kit

 

Product Report

Package Insert

Product Sheet

Sheet

You may also like

Recently viewed